112 results on '"C.F. Perno"'
Search Results
2. CARATTERIZZAZIONE DEI PROFILI DI RESISTENZA A LAMIVUDINA ED ADEFOVIR IN PAZIENTI CON EPATITE B CRONICA
3. CONFRONTO TRA DUE DOSAGGI IN REAL-TIME PER LA DETERMINAZIONE QUANTITATIVA DI HCV-RNA
4. CARATTERIZZAZIONE BIOLOGICA DI HIV-1 ISOLATO DURANTE UN’INFEZIONE PRIMARIA ASSOCIATA AD UNA SINDROME EMOFAGOCITICA SEVERA
5. HIV MDR is still a relevant issue despite its dramatic drop over the years
6. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C
7. Quantitative HBeAg varies across the different phases of HBV infection, and can predict treatment outcome in the setting of HBV-reactivation driven by iatrogenic immunosuppression
8. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
9. Key mutations in HBsAg C-terminus correlate with lower HBsAg levels in vivo, hinder HBsAg release in vitro and affect HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection
10. The combined usage of accurate virological and serological HBV markers can help to identify HBsAg-negative/anti-HBc-positive patients at higher risk of HBV-reactivation and to optimize prophylaxis duration in oncohematological setting
11. A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro
12. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
13. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
14. The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification
15. Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA
16. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?
17. In HBeAg-negative chronic HBV infection, HBsAg levels profoundly differ among HBV-genotypes and can be affected by the extent of HBsAg variability : Can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?
18. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy
19. Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy
20. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?
21. The levels of middle surface HBVantigen increase in patients with HBV-driven liver cancer despite prolonged virological suppression: implications for a novel marker of HBV-driven hepatocarcinogenesis
22. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
23. Key mutational patterns in HBsAg C-terminus profoundly affect HBsAg levels in HBeAg-negative chronic HBV genotype D infection
24. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy
25. National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
26. HEV infection: an emerging disease. One year observation in a tertiary care center in Milan
27. A close monitoring of virological and immunological hepatitis B markers can improve the diagnosis of HBV reactivation in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
28. The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative chronic infection: implications for an altered cell homeostasis and metabolism
29. VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT
30. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment
31. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
32. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
33. An outbreak of acute hepatitis C GT1b in onco-hematological patients. Treatment with Sofosbuvir + Ledipasvir and concomitant chemotherapy
34. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
35. Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapies
36. Basal core promoter mutations as potential predictors of an enlarged intrahepatic HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B infection
37. Combination of HBV serological markers to predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg negative Chronic Hepatitis B
38. HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B
39. A hyper-glycosylation of HBV surface major hydrophilic region correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro
40. Early-phase hcv kinetics and role of pre-existing resistance in cirrhotic or interferon-insensitive patients on daclatasvir plus asunaprevir
41. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management
42. HBV-HDV co-infection constrains HBV genetic evolution in HBsAg
43. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting
44. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents
45. Vaccine-escape HBsAg mutants circulating among genotype D HBV-infected patients correlate with atypical serological profiles, high viremia and transaminases: Potential impact on vaccination strategies
46. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment
47. Immunosuppression-driven HBV reactivation in patients with resolved HBV infection correlates with a relevant risk of death and with evolution towards active chronical infection
48. Different Prevalence of HCV Resistance and HCV RNA Quantification Within Tumoral and Non Tumoral Liver Tissues in HCC/Transplanted Patients
49. A High Density of Mutations within HLA Class I and II HBsAg/RT Epitopes Characterizes HBV Variants Emerging during Immune-Suppression Driven HBV Reactivation
50. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.